Blog
RSS FeedPosted by Michael Wonder on 05 Jul 2018
Health Canada approves Erleada (apalutamide tablets), the first treatment for men with non-metastatic castration-resistant prostate cancer
4 July 2018 - Erleada decreased the risk of metastasis or death in patients by 70% and improved median metastasis-free survival ...
Posted by Michael Wonder on 14 Jun 2018
Alecensaro (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer
13 June 2018 - Targeted oral treatment shown to reduce risk of death or disease progression by more than half compared ...
Posted by Michael Wonder on 11 May 2018
Lynparza (olaparib) receives new indication for BRCA-mutated metastatic breast cancer
10 May 2018 - Lynparza has been shown to reduce the risk of disease progression or death by 42% compared ...
Posted by Michael Wonder on 10 May 2018
First and only immuno-oncology treatment, Imfinzi (durvalumab), for stage III, unresectable non-small-cell lung cancer now approved in Canada
9 May 2018 - Patients receiving Imfinzi in the PACIFIC clinical trial lived for nearly one year without their disease ...
Posted by Michael Wonder on 09 May 2018
Lynparza (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status
8 May 2018 - The treatment demonstrates a 65% reduction in disease progression or death. ...
Posted by Michael Wonder on 02 May 2018
Health Canada approves Kisqali for the treatment of HR-positive and HER2-negative metastatic breast cancer in post-menopausal women in combination with letrozole as an initial endocrine-based therapy
2 May 2018 - Arrival of new first-line therapy provides additional option for those living with this advanced form of breast ...
Posted by Michael Wonder on 09 Apr 2018
Health Canada approves Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small-cell lung cancer
9 April 2018 - Tecentriq provides a new cancer immunotherapy option for Canadians living with the difficult disease. ...
Posted by Michael Wonder on 07 Apr 2018
Besponsa approved by Health Canada for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
6 April 2018 - First and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory CD22-positive ...
Posted by Michael Wonder on 23 Mar 2018
Health Canada approves Rituxan subcutaneous formulation for Canadians with chronic lymphocytic leukaemia
22 March 2018 - Rituxan SC is a new treatment option for Canadians living with one of the most common forms ...
Posted by Michael Wonder on 21 Mar 2018
BMS withdraws submission for Opdivo for urothelial carcinoma
20 March 2018 - Health Canada's handling of the submission is perplexing. ...
Posted by Michael Wonder on 07 Mar 2018
Health Canada approves Lonsurf (trifluridine/tipiracil) for metastatic colorectal cancer
6 March 2018 - Lonsurf, a new important treatment option for adult patients with metastatic colorectal cancer that has been shown ...
Posted by Michael Wonder on 23 Feb 2018
Health Canada approves Bavencio (avelumab for injection) for the treatment of metastatic Merkel cell carcinoma in previously treated adult patients
22 February 2018 - First Health Canada approved treatment for rare and aggressive type of skin cancer. ...
Posted by Michael Wonder on 16 Feb 2018
Health Canada approves new indication for Zytiga (abiraterone acetate), broadening its use for treatment of newly diagnosed metastatic prostate cancer
15 February 2018 - Zytiga, used in combination with prednisone and androgen deprivation therapy, was shown to reduce the risk ...
Posted by Michael Wonder on 14 Feb 2018
Health Canada approves Ipsen's Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours
13 February 2018 - Somatuline Autogel is the first and only somatostatin analog approved in Canada to treat enteropancreatic neuroendocrine ...
Posted by Michael Wonder on 04 Feb 2018
Tagrisso (osimertinib) receives full Health Canada approval for targeted treatment of non-small-cell lung cancer
31 January 2018 - Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with Tagrisso compared ...